Press Releases

11-15-2022	Pliant Therapeutics to Participate in Upcoming Investor Conferences
11-08-2022	Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
10-05-2022	Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
09-15-2022	Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors
09-01-2022	Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
08-30-2022	Pliant Therapeutics to Participate in Upcoming Investor Conferences
08-08-2022	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
08-02-2022	Pliant Therapeutics to Participate in BTIG Biotechnology Conference
07-21-2022	Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis
07-15-2022	Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Investors & Media